Form 4: Sight Sciences Director and 10% Owner Staffan Encrantz Boosts Stake with Nearly 100,000 Share Purchase

Staffan Encrantz, a Director and 10% owner of Sight Sciences, Inc., has significantly increased his direct beneficial ownership by purchasing 98,782 shares of common stock across three transactions in late May and early June 2025.

Summary

• Staffan Encrantz, identified as both a Director and a 10% owner of Sight Sciences, Inc. (SGHT), reported multiple acquisitions of the company's common stock.
• On May 30, 2025, Mr. Encrantz acquired 42,753 shares of common stock at a weighted average price of $3.67 per share, with transaction prices ranging from $3.505 to $3.715.
• On June 2, 2025, an additional 30,799 shares were purchased at a weighted average price of $3.878 per share, with prices ranging from $3.65 to $3.91.
• A third transaction occurred on June 3, 2025, involving the acquisition of 25,230 shares at a weighted average price of $3.967 per share, with prices ranging from $3.85 to $4.00.
• Following these transactions, Mr. Encrantz's direct beneficial ownership stands at 1,256,487 shares, which includes 1,239,121 shares of common stock and 17,366 restricted stock units.
• Additionally, Mr. Encrantz indirectly beneficially owns 632,456 shares through the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust, where he serves as a trustee.
• He also indirectly beneficially owns 5,086,920 shares held by Allegro Investment Fund, L.P., where he is the President and sole director of the investment manager, Allegro Investment Inc., though he disclaims pecuniary interest in these shares.

Sentiment

Score: 8

Explanation: The sentiment is strongly positive due to significant insider buying by a director and 10% owner, which typically signals strong confidence in the company's valuation and future performance.

Positives

• The reporting person, a Director and 10% owner, engaged in significant open market purchases, acquiring a total of 98,782 shares, which typically signals confidence in the company's future prospects.
• The consistent buying activity across multiple days suggests a deliberate increase in stake by a key insider.

Future Outlook

NA

Industry Context

This Form 4 filing reflects an individual insider's trading activity and does not provide broader industry context or trends. However, significant insider buying can be interpreted as a positive signal within the medical device or ophthalmology sector, suggesting internal confidence in the company's market position or future product pipeline.

Related Party Transactions

• The reporting person indirectly holds 632,456 shares through the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust, where he is a trustee.
• The reporting person indirectly holds 5,086,920 shares through Allegro Investment Fund, L.P., where he is the President and sole director of the investment manager, Allegro Investment Inc., though he disclaims pecuniary interest in these shares.

Stakeholder Impact

• Shareholders may view the significant insider buying as a positive indicator, potentially increasing investor confidence and demand for the stock.
• The increased stake by a director and 10% owner aligns the interests of management more closely with those of other shareholders.

Key Dates

Recommendation

Keywords

Sight Sciences, SGHT, Form 4, Insider Buying, Stock Purchase, Beneficial Ownership, Director, 10% Owner, Staffan Encrantz, Equity Acquisition